Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 12:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–14 of 14 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma
Interventions
CAT-8015 (Moxetumomab Pasudotox)
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
6 Months to 25 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
4
States / cities
Los Angeles, California • Bethesda, Maryland • Boston, Massachusetts + 1 more
Conditions
Leukemia, Lymphoma, Chronic Lymphocytic, Leukemia, Prolymphocytic Leukemia, Small, Lymphocytic Lymphoma, Moxetumomab Pasudotox
Interventions
CAT-8015 5 mcg/kg, CAT-8015 10 mcg/kg, CAT-8015 20 mcg/kg
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Indianapolis, Indiana • Bethesda, Maryland
Conditions
Leukemia, Lymphoma
Interventions
BL22 immunotoxin, antibody-drug conjugate therapy, immunotoxin therapy, monoclonal antibody therapy
Drug · Procedure
Lead sponsor
MedImmune LLC
Industry
Eligibility
6 Months to 24 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Leukemia
Interventions
Immunotoxin therapy, CAT-8015 immunotoxin, Biological therapy
Drug · Procedure
Lead sponsor
Cambridge Antibody Technology
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
3
States / cities
Beverly Hills, California • Indianapolis, Indiana • Bethesda, Maryland
Conditions
Leukemia
Interventions
Moxetumomab Pasudotox
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Houston, Texas
Conditions
Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
Interventions
CAT-8015 20 mcg/kg, CAT-8015 30 mcg/kg, CAT-8015 40 mcg/kg, CAT-8015 50 mcg/kg, CAT-8015 60 mcg/kg
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
7
States / cities
Los Angeles, California • Indianapolis, Indiana • Bethesda, Maryland + 4 more
Completed Phase 3 Interventional Results available

Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia

NCT01829711
Conditions
Leukemia, Hairy Cell
Interventions
Moxetumomab pasudotox, IV Bag Protectant for Moxetumomab pasudotox
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 100 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
9
States / cities
Duarte, California • Los Angeles, California • Miami, Florida + 6 more
Conditions
Leukemia, Hairy Cell Leukemia, HCL
Interventions
Immunotoxin therapy, CAT-8015 Immunotoxin, Biological therapy
Drug · Procedure
Lead sponsor
Cambridge Antibody Technology
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
3
States / cities
Stanford, California • Chicago, Illinois • Bethesda, Maryland
Conditions
Leukemia, Non-Hodgkin's Lymphoma, NHL
Interventions
Immunotoxin therapy, CAT-8015 Immunotoxin, Biological therapy, Antibody Therapy, Monoclonal Antibody Therapy
Drug · Procedure
Lead sponsor
Cambridge Antibody Technology
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
2
States / cities
Beverly Hills, California • Bethesda, Maryland
Conditions
Hairy Cell Leukemia
Interventions
Moxetumomab Pasudotox-tdfk, Rituximab, Ruxience, Dexamethasone, Acetaminophen, Diphenhydramine, Famotidine, Aspirin
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Acute Lymphoblastic Leukemia (ALL)
Interventions
Moxetumomab Pasudotox
Biological
Lead sponsor
Center for International Blood and Marrow Transplant Research
Network
Eligibility
6 Months to 24 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2015
U.S. locations
4
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 1 more
Conditions
B-Cell Pediatric ALL
Interventions
Moxetumomab Pasudotox
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
6 Months to 18 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
10
States / cities
Phoenix, Arizona • Los Angeles, California • Chicago, Illinois + 7 more
Conditions
Hairy Cell Leukemia
Interventions
Moxetumomab Pasudotox (CAT 8015), CAT 8015 (Moxetumomab Pasudotox)
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
3
States / cities
Stanford, California • Chicago, Illinois • Bethesda, Maryland
Conditions
Lymphoma
Interventions
CAT-8015
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Beverly Hills, California • Bethesda, Maryland